Logotype for Oculis Holding AG

Oculis (OCS) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Oculis Holding AG

Q3 2026 earnings summary

4 Nov, 2026

Executive summary

  • Late-stage pipeline advanced: PREDICT-1 completed randomization, while PIONEER-1 continued site activation and enrollment; topline PREDICT-1 results are expected around year-end 2026.

  • Privosegtor’s Phase 2 biomarker findings and prior functional and structural results support its potential neuroprotective activity in optic neuritis and acute MS relapses.

Financial highlights

  • Cash, cash equivalents and short-term investments totaled CHF 210.3M ($252.0M) at Sept. 30, 2026, versus CHF 213.0M ($268.7M) at Dec. 31, 2025; runway extends into 2H 2029.

  • Q3 2026 R&D expense was CHF 15.1M ($18.5M), versus CHF 14.1M ($17.6M) in Q3 2025; G&A was CHF 8.6M ($10.6M), versus CHF 6.4M ($8.0M).

  • 9M 2026 net loss was CHF 57.1M ($71.7M), versus CHF 75.4M ($89.7M) in 9M 2025; lower loss reflected warrant fair-value gains and favorable FX movements.

Outlook and guidance

  • PREDICT-1 topline results are anticipated around year-end 2026; positive results could support Licaminlimab as a precision medicine for TNFR1-mediated dry eye disease.

  • FDA IND clearance for Privosegtor trials in acute MS relapses is expected in Q4 2026, following positive FDA feedback on the regulatory pathway.

  • R&D Day is scheduled for Dec. 8, 2026, with updates planned on Licaminlimab and Privosegtor programs, including optic neuritis, NAION and acute MS relapses.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Oculis